1-3 of 3
Eduard Gasal
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib

Jan C. Brase, Robert F.H. Walter, Alexander Savchenko, Daniel Gusenleitner, James Garrett, Tobias Schimming, Renata Varaljai, Deborah Castelletti, Ju Kim, Naveen Dakappagari, Ken Schultz, Caroline Robert, Georgina V. Long, Paul D. Nathan, Antoni Ribas, Keith T. Flaherty, Boguslawa Karaszewska, Jacob Schachter, Antje Sucker, Kurt W. Schmid, Lisa Zimmer, Elisabeth Livingstone, Eduard Gasal, Dirk Schadendorf, Alexander Roesch
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4500–4510.
https://doi.org/10.1158/1078-0432.CCR-20-3586
Published: 15 August 2021
View article titled, Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
Open the PDF for Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib in another window
Includes: Supplementary data
Journal Articles

BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

Gary Middleton, Yiqun Yang, Catarina D. Campbell, Thierry André, Chloe E. Atreya, Jan H.M. Schellens, Takayuki Yoshino, Johanna C. Bendell, Antoine Hollebecque, Autumn J. McRee, Salvatore Siena, Michael S. Gordon, Josep Tabernero, Rona Yaeger, Peter J. O'Dwyer, Filip De Vos, Eric Van Cutsem, John M. Millholland, Jan C. Brase, Fatima Rangwala, Eduard Gasal, Ryan B. Corcoran
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (11): 2466–2476.
https://doi.org/10.1158/1078-0432.CCR-19-3579
Published: 01 June 2020
View article titled, <em>BRAF</em>-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer
Open the PDF for <em>BRAF</em>-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study

Darren R. Hargrave, Eric Bouffet, Uri Tabori, Alberto Broniscer, Kenneth J. Cohen, Jordan R. Hansford, Birgit Geoerger, Pooja Hingorani, Ira J. Dunkel, Mark W. Russo, Lillian Tseng, Kohinoor Dasgupta, Eduard Gasal, James A. Whitlock, Mark W. Kieran
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (24): 7303–7311.
https://doi.org/10.1158/1078-0432.CCR-19-2177
Published: 13 December 2019
View article titled, Efficacy and Safety of Dabrafenib in Pediatric Patients with <em>BRAF</em> V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study
Open the PDF for Efficacy and Safety of Dabrafenib in Pediatric Patients with <em>BRAF</em> V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study in another window
Includes: Supplementary data